Alopecia areata (AA) is an autoimmune T CD8 cell mediated condition clinically characterized by hair loss from single or few small patches to complete hair loss. The management of AA is challenging and all available therapies does not ensure a long-term remission. To assess the safety and efficacy of both systemic and topical brevilin A, a natural compound, in AA patients not responding to other treatments. After obtaining informed consent, we administered off-label brevilin A to 13 adult patients affected by AA, for a period ranging from 6 to 18 months. Medical records for each patient and the severity of alopecia tool (SALT) score before and after brevilin A administration were recorded. The mean SALT score of our patients was 81.03 (SD 34.9) at baseline and 75.8 (SD 37.4) after brevilin A therapy, meaning no statistically significant improvement was observed (P = .2385 Paired t test). However, three multifocal AA (MAA) patients out of four attained an improvement (75%) suggesting that brevilin A may be represent an alternative therapy in this form of AA. Authors conclude that brevilin A could represent in the future a possible effective treatment in MAA forms but further studies are required.

Alopecia areata treated with topical and systemic brevilin A: A case series / Muscianese, Marta; Magri, Francesca; Leoncini, Pierpaolo; Fortuna, Maria Caterina; Caro, Gemma; Rossi, Alfredo. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2021). [10.1111/dth.14778]

Alopecia areata treated with topical and systemic brevilin A: A case series

Marta Muscianese
Primo
;
Francesca Magri;Maria Caterina Fortuna;Gemma Caro;Alfredo Rossi
Ultimo
2021

Abstract

Alopecia areata (AA) is an autoimmune T CD8 cell mediated condition clinically characterized by hair loss from single or few small patches to complete hair loss. The management of AA is challenging and all available therapies does not ensure a long-term remission. To assess the safety and efficacy of both systemic and topical brevilin A, a natural compound, in AA patients not responding to other treatments. After obtaining informed consent, we administered off-label brevilin A to 13 adult patients affected by AA, for a period ranging from 6 to 18 months. Medical records for each patient and the severity of alopecia tool (SALT) score before and after brevilin A administration were recorded. The mean SALT score of our patients was 81.03 (SD 34.9) at baseline and 75.8 (SD 37.4) after brevilin A therapy, meaning no statistically significant improvement was observed (P = .2385 Paired t test). However, three multifocal AA (MAA) patients out of four attained an improvement (75%) suggesting that brevilin A may be represent an alternative therapy in this form of AA. Authors conclude that brevilin A could represent in the future a possible effective treatment in MAA forms but further studies are required.
2021
alopecia areata; brevilin a; Crotonates
01 Pubblicazione su rivista::01a Articolo in rivista
Alopecia areata treated with topical and systemic brevilin A: A case series / Muscianese, Marta; Magri, Francesca; Leoncini, Pierpaolo; Fortuna, Maria Caterina; Caro, Gemma; Rossi, Alfredo. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2021). [10.1111/dth.14778]
File allegati a questo prodotto
File Dimensione Formato  
Muscianese_Alopecia_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.51 MB
Formato Adobe PDF
1.51 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1499964
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact